Browse

Autoantibody to DNA binding protein B as a novel serologic marker in systemic sclerosis

DC Field Value Language
dc.contributor.authorJeoung, Doo-il-
dc.contributor.authorLee, Eun Bong-
dc.contributor.authorLee, Seongeun-
dc.contributor.authorLim, Yoon-
dc.contributor.authorLee, Dae-Yeon-
dc.contributor.authorKim, Jongwan-
dc.contributor.authorKim, Hae-Yeong-
dc.contributor.authorWook Song, Yeong-
dc.date.accessioned2009-11-13T04:30:24Z-
dc.date.available2009-11-13T04:30:24Z-
dc.date.issued2002-
dc.identifier.citationBiochem. Biophys. Res. Commun. 299 (4) (2002) 549-554en
dc.identifier.issn0006-291X (Print)-
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12459173-
dc.identifier.urihttp://hdl.handle.net/10371/12123-
dc.description.abstractSystemic sclerosis is a systemic disease that is characterized by tissue fibrosis, small-vessel vasculopathy, and an autoimmune response associated with autoantibodies. We performed serological analysis of cDNA expression library (SEREX) to identify autoantibodies associated with systemic sclerosis. We identified 4 clones that react with sera of patients with SSc but not with those of healthy donors. These clones are phosphoglycerate mutase, centromere autoantigen C, U1 small nuclear ribonucleoprotein, and DNA binding protein B (dbpB). We chose to study autoantibody to DNA binding protein B. Immunoreactivity against recombinant dbpB was detected in 40.5% (15/37) of patients with SSc, 14.6% (6/41) of patents with systemic lupus erythematosus, 6.7% (1/15) of patients with rheumatoid arthritis, 0% (0/12) of patients with Sjogren syndrome, and 5.9% (1/17) of patients with polymyositis/dermatomyositis. The frequency of anti-dbpB was significantly higher in the SSc patients (15/37, 40.5%) compared to the healthy controls (3/41, 7.3%, p=0.0005 by chi(2) test). Eleven patients (11/20, 55%) with the diffuse cutaneous type of SSc had anti-dbpB and 4 patients (4/17, 23.5%) with the limited cutaneous type had anti-dbpB. The presence of anti-dbpB was significantly associated with the diffuse cutaneous type (p=0.00003 by chi(2) test). This is the first report to suggest that autoantibody to dbpB can be used as a serologic marker of systemic sclerosis.en
dc.language.isoen-
dc.publisherElsevieren
dc.subjectAutoantibodies/*blooden
dc.subjectBiological Markersen
dc.subjectCCAAT-Enhancer-Binding Proteins/*immunology/metabolismen
dc.subject*DNA-Binding Proteinsen
dc.subjectGene Libraryen
dc.subjectNFI Transcription Factorsen
dc.subjectNuclear Proteinsen
dc.subjectScleroderma, Systemic/blood/diagnosis/*immunologyen
dc.subjectSerologic Testsen
dc.subjectTranscription Factors/immunology/metabolismen
dc.subjectY-Box-Binding Protein 1en
dc.titleAutoantibody to DNA binding protein B as a novel serologic marker in systemic sclerosisen
dc.typeArticleen
dc.contributor.AlternativeAuthor정두일-
dc.contributor.AlternativeAuthor이은봉-
dc.contributor.AlternativeAuthor임윤-
dc.contributor.AlternativeAuthor이대연-
dc.contributor.AlternativeAuthor김종완-
dc.contributor.AlternativeAuthor김해영-
dc.contributor.AlternativeAuthor이성은-
dc.identifier.doi10.1016/S0006-291X(02)02685-2-
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Internal Medicine (내과학전공)Journal Papers (저널논문_내과학전공)
Files in This Item:
There are no files associated with this item.
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse